Feb 18 (Reuters) - Unnatural Products said on Wednesday it has signed a licensing agreement with Novartis to develop macrocyclic peptide-based therapies for a cardiovascular program. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results